Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials

Metastatic prostate cancer continues to be an incurable disease. Despite all the novel therapies approved in the past two decades, overall patient outcomes remain relatively poor, and these patients die on a regular basis. Clearly, improvements in current therapies are needed. Prostate-specific memb...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Albert, Kendi, Ayse T., Sartor, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Advancing and Innovating in the Era of PSMA theranostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989419/
https://www.ncbi.nlm.nih.gov/pubmed/36895851
http://dx.doi.org/10.1177/17588359231157632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989419/
https://www.ncbi.nlm.nih.gov/pubmed/36895851
http://dx.doi.org/10.1177/17588359231157632

Ejemplares similares